RAD001 is the research name/code for a new  investigational medication made by Novartis. The active ingredient in RAD001 is everolimus, which is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the Europe in 2003. Certican is not approved in the US.

At this time, RAD001 is only available to cancer patients in clinical studies such as Pillar-1. RAD001 is also being studied as a treatment for patients with various cancers, either alone or in combination with other cancer treatments. Experiments have shown that RAD001 may stop certain cancer cells from multiplying. RAD001 may also block the formation of the blood vessels that a tumor needs to grow and spread.

To see if you qualify for this important Novartis research study, click on the link below.